Coloplast has increased investment in company behind vapor therapy

In September, the medtech company Francis Medical has raised USD 55m for the further development of a potential water vapor ablation therapy for the treatment of prostate cancer. Coloplast – which was already one of its investors – has used the opportunity to invest even further in the US-based company.

Photo: Coloplast / PR

Coloplast's faith in a potential vapor ablation treatment for prostate cancer has grown stronger, having participated in a series B equity financing round of the US-based medtech company behind the treatment, the Danish company reports in its year-end report from 2020/2021.

Francis Medical has previously announced that the Series B financing round has brought the company USD 55m in funding. The Series B round was led by venture capital firm Solas Bioventures with previous investors participating, including Coloplast, which became an investor in the company with USD 4m in September 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs